Towards liquid biopsy-based analysis of antitumour immunity.
A framework for monitoring cancer-fighting immune cells in blood could help doctors personalize immunotherapy by detecting early signs of response or resistance without repeated biopsies.
This Nature Reviews Clinical Oncology review by world-leading liquid biopsy experts Pantel and Alix-Panabières proposes a comprehensive paradigm for characterizing antitumour immunity non-invasively, combining CTC, EV, cfDNA, and immune cell analytes into integrated immune monitoring platforms. The framework addresses a critical unmet gap in non-invasive immunotherapy response monitoring and guides next-generation liquid biopsy tool development for early cancer detection and treatment adaptation.
What the study was
- Study design
- Expert narrative review and conceptual framework
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- Nature reviews. Clinical oncology
Why it surfaced
Nat Rev Clin Oncol review by two foremost liquid biopsy authorities proposing immune-based liquid biopsy framework. Sets agenda for next-generation liquid biopsy integrating antitumour immunity. Broadly applicable across cancer types; addresses critical immunotherapy monitoring gap.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.